Provided by Tiger Trade Technology Pte. Ltd.

Veru Inc.

2.46
-0.0100-0.40%
Post-market: 2.480.0200+0.81%17:16 EDT
Volume:201.61K
Turnover:498.37K
Market Cap:41.94M
PE:-4.20
High:2.54
Open:2.42
Low:2.41
Close:2.47
52wk High:7.33
52wk Low:2.05
Shares:17.05M
Float Shares:15.48M
Volume Ratio:0.51
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5854
EPS(LYR):-1.5517
ROE:-64.54%
ROA:-54.03%
PB:1.48
PE(LYR):-1.59

Loading ...

Veru Q3 EPS $(0.30) Beats $(0.32) Estimate

Benzinga Earnings
·
Aug 10

Veru FY26 Q3 Net Loss Narrows to $7 Million; R&D Expense Rises 44% to $4.4 Million

Reuters
·
Aug 10

Veru - Phase 2B Plateau Trial Fully Enrolled with 239 Patients

THOMSON REUTERS
·
Aug 10

Veru Q3 EPS USD -0.3

THOMSON REUTERS
·
Aug 10

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2B Plateau Clinical Trial Progress

THOMSON REUTERS
·
Aug 10

Press Release: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Plateau Clinical Trial Progress

Dow Jones
·
Aug 10

Veru Inc. Expected to Post a Loss of 32 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Veru Wins US Patent Allowance for Enobosarm-Semaglutide Weight-Loss Regimen Claims

Reuters
·
Aug 04

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

THOMSON REUTERS
·
Aug 04

Veru - Interim Analysis Results Expected Q1 2027; Final Topline Data Expected Q4 2027

THOMSON REUTERS
·
Aug 04

Veru Schedules Conference Call on Quarterly Financial Results and Business Update

Reuters
·
Aug 03

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

GlobeNewswire
·
Aug 03

Veru CEO Steiner Joins Canaccord Genuity Growth Investors Conference Fireside Chat

Reuters
·
Jul 30

Veru completes enrollment in PLATEAU clinical study

TIPRANKS
·
Jul 27

Veru Completes Enrollment in Phase 2 Obesity Study

MT Newswires Live
·
Jul 27

Veru Completes Enrollment in Phase 2b Plateau Trial of Enobosarm with Semaglutide in Older Obesity Patients

Reuters
·
Jul 27

Veru Announces Full Enrollment for Phase 2B Plateau Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

THOMSON REUTERS
·
Jul 27

Veru - Interim Analysis Results for Phase 2B Plateau Trial Expected in Q1 2027

THOMSON REUTERS
·
Jul 27

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

GlobeNewswire
·
Jul 07

Veru - Enters Sales Agreement with Oppenheimer & Co. and Canaccord Genuity on July 2, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 03